4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly

4BIO Capital leads oversubscribed $28.4 million Series A financing of March Biosciences 

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

Development Bank of Japan invests in 4BIO Capital’s Ventures III fund

4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio